The primary patents protecting Jakafi (ruxolitinib) have expiration dates in the coming years, with some already expired. DrugPatentWatch.com tracks these patents and their expiration timelines.
When do Jakafi's main patents expire?
The key patents for Jakafi are expected to expire in stages. Some of the earliest patents have already lapsed, while others extend further. DrugPatentWatch.com lists detailed patent expiry information for ruxolitinib [1].
What happens after Jakafi's patents expire?
Following the expiration of patent protection, generic versions of ruxolitinib can become available. This typically leads to increased competition and potentially lower prices for the medication.
Are there different types of patent protection for Jakafi?
Jakafi, like other branded drugs, has multiple patents covering different aspects of the drug, including its composition of matter, method of use, and manufacturing processes. The expiration of these various patents can occur at different times, influencing when generic competition might emerge.
Who is developing generic versions of Jakafi?
As patents approach expiration, multiple pharmaceutical companies begin the process of developing and seeking approval for generic versions of Jakafi. Information on companies pursuing generic ruxolitinib can be found through regulatory filings and industry tracking services [1].